Andrew Hack - Jun 12, 2024 Form 4 Insider Report for Nuvalent, Inc. (NUVL)

Role: Director
Signature: /s/ Andrew Hack
Stock symbol: NUVL
Transactions as of: Jun 12, 2024
Transactions value $: $0
Form type: 4
Date filed: 6/14/2024, 04:53 PM
Previous filing: Jun 12, 2024

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	NUVL	Class A Common Stock	Award		+2.5K			2.5K	Jun 12, 2024	Direct	F1
holding	NUVL	Class A Common Stock						2.7M	Jun 12, 2024	See footnotes	F3, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	NUVL	Stock Option (right to buy)	Award	$0	+3.79K		$0.00	3.79K	Jun 12, 2024	Class A Common Stock	3.79K	$80.03	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The shares reported in this transaction represent Restricted Stock Units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Class A Common Stock. 100% of the RSUs subject to this grant will vest on the earlier of June 12, 2025 or the date of the Issuer's next annual meeting of stockholders, subject to continued service to the Issuer through such vesting date.
F2	The shares underlying this option will vest in full on the earlier of June 12, 2025 or the date of the Issuer's next annual meeting of stockholders, subject to continued service to the Issuer through such vesting date.
F3	Represents shares of Class A Common Stock held directly by Bain Capital Life Sciences Fund II, L.P. ("BCLS Fund II"), BCIP Life Sciences Associates, LP ("BCIPLS") and BCLS II Investco, LP ("BCLS II Investco" and, together with BCLS Fund II and BCIPLS, the "Bain Capital Life Sciences Entities").
F4	Bain Capital Life Sciences Investors, LLC ("BCLSI") is the ultimate general partner of each of BCLS Fund II and BCLS II Investco and governs the investment strategy and decision-making process with respect to investments held by BCIPLS. Dr. Hack is a Partner of BCLSI. By virtue of the relationships described in this footnote, Dr. Hack may be deemed to share voting and dispositive power with respect to the securities held by the Bain Capital Life Sciences Entities. Dr. Hack disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.